There has been a new medical breakthrough in the fight against myeloid leukemia or AML.<br />A new drug for AML improves overall survival in people with the deadly blood cancer by up to 10 months.<br />That's according to the results of a Phase 3 clinical trial published Thursday by the New England Journal of Medicine.<br />The study conducted at 148 hospitals in 23 countries.<br />The drug is called CC-486.<br />UPI health reports the CC-486 improved survival in patients age 55 and older.<br />"It is very exciting to think that, by taking a tablet that is relatively well-tolerated, we can help reduce relapse risk and improve survival," study co-author Dr. Andrew Wei said in a press release.
